Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19864844 | 0.79 | LMNA (0.37) | NOS1LMNA | |
| SCHEMBL9682575 | 0.75 | IDO1 (0.38) | NOS1LMNA | |
| SCHEMBL2953500 | 0.74 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1LMNANOS3NOS2 | |
| SCHEMBL1396931 | 0.72 | LMNA (0.35) | NOS1ALDH1A1L3MBTL1LMNANOS3 | |
| SCHEMBL10918419 | 0.72 | ALDH1A1 (0.43) | NOS1ALDH1A1L3MBTL1LMNANOS3 | |
| SCHEMBL6474069 | 0.68 | CDK1 (0.35) | ALDH1A1L3MBTL1LMNANOS3NOS2 | |
| SCHEMBL9466064 | 0.68 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1LMNANOS3NOS2 | |
| SCHEMBL19978957 | 0.68 | — | — | |
| SCHEMBL10522523 | 0.67 | KDM5B (0.30) | — | |
| SCHEMBL18520121 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411425-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411425-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CCR5, CD4, NFATC1 | NOS1 3881/4885ALDH1A1 1598/4885L3MBTL1 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.